ImClone Systems Incorporated. U.S. Food and Drug Administration. Erbitux (cetuximab) prescribing information. 2019.
European Medicines Agency. European public assessment report for Erbitux (cetuximab). 2020.
Phelip JM, Tougeron D, Léonard D, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51(10):1357–63.
Article
PubMed
Google Scholar
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2006;354(6):567–78.
Article
CAS
PubMed
Google Scholar
Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359(11):1116–27.
Article
CAS
PubMed
Google Scholar
Machiels J-P, René Leemans C, Golusinski W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75.
Article
PubMed
Google Scholar
Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med. 2007;357(20):2040–8.
Article
CAS
PubMed
Google Scholar
Cunningham D, Humblet Y, Siena S, et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med. 2004;351(4):337–45.
Article
CAS
PubMed
Google Scholar
Foley KA, Wang PF, Barber BL, et al. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann Oncol. 2010;21(7):1455–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yamaguchi K, Watanabe T, Satoh T, et al. Severe Infusion Reactions to Cetuximab Occur within 1 h in Patients with Metastatic Colorectal Cancer: Results of a Nationwide, Multicenter, Prospective Registry Study of 2126 Patients in Japan. Jpn J Clin Oncol. 2014;44(6):541–6.
Article
PubMed
PubMed Central
Google Scholar
Song X, Long R, Barber S. B et al. Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer. Curr Clin Pharmacol. 2012;7(1):56–65.
Article
CAS
PubMed
Google Scholar
Chung CH, Mirakhur B, Chan E, et al. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose. N Engl J Med. 2008;358(11):1109–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Platts-Mills TAE, Li RC, Keshavarz B, et al. Diagnosis and Management of Patients with the alpha-Gal Syndrome. J Allergy Clin Immunol Pract. 2020;8(1):15–23.e1.
Article
PubMed
Google Scholar
Chinuki Y, Morita E. Alpha-Gal-containing biologics and anaphylaxis. Allergol Int. 2019;68(3):296–300.
Article
CAS
PubMed
Google Scholar
Commins SP. Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients. Expert Rev Clinical Immunol. 2020;16(7):667–77.
Article
Google Scholar
de la Fuente J, Pacheco I, Villar M, et al. The alpha-Gal syndrome: new insights into the tick-host conflict and cooperation. Parasit Vectors. 2019;12(1):154.
Article
PubMed
PubMed Central
Google Scholar
Chung CH. Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy. Oncologist. 2008;13(6):725–32.
Article
CAS
PubMed
Google Scholar
Ikegawa K, Suzuki S, Nomura H, et al. Retrospective analysis of premedication, glucocorticosteroids, and H 1 -antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. J Int Med Res. 2017;45(4):1378–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer. 2010;116(7):1827–37.
Article
CAS
PubMed
Google Scholar
Durham CG, Thotakura D, Sager L, et al. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. J Oncol Pharm Pract. 2019;25(6):1396–401.
Article
CAS
PubMed
Google Scholar
O’Neil BH, Allen R, Spigel DR, et al. High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History. J Clin Oncol. 2007;25(24):3644–8.
Article
PubMed
Google Scholar
Hansen NL, Chandiramani DV, Morse MA, et al. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract. 2011;17(2):125–30.
Article
CAS
PubMed
Google Scholar
Atwal D, Safar AM, Govindarajan R, Makhoul I. Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. J Oncol Pharm Pract. 2019;25(5):1130–4.
Article
CAS
PubMed
Google Scholar
Touma W, Koro SS, Ley J, et al. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(9):895–900.
Article
CAS
PubMed
PubMed Central
Google Scholar
Waqar SN, Tan BR, Zubal B, et al. Race and albuterol premedication are risk factors for hypersensitivity reactions to cetuximab. J Clin Oncol. 2008;26(15_suppl):20503.
Article
Google Scholar
George TJ, Laplant KD, Walden EO, et al. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol. 2010;8(2):72–7.
CAS
PubMed
Google Scholar
Grandvuillemin A, Disson-Dautriche A, Miremont-Salamé G, et al. Cetuximab infusion reactions: French pharmacovigilance database analysis. J Oncol Pharm Pract. 2013;19(2):130–7.
Article
PubMed
Google Scholar
Hopps S, Medina P, Pant S, et al. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract. 2013;19(3):222–7.
Article
CAS
PubMed
Google Scholar
Palomar Coloma V, Bravo P, Lezghed N, et al. High incidence of cetuximab-related infusion reactions in head and neck patients. ESMO Open. 2018;3(5):e000346.
Article
PubMed
PubMed Central
Google Scholar
Keating K, Walko C, Stephenson B, et al. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. J Oncol Pharm Pract. 2014;20(6):409–16.
Article
PubMed
Google Scholar
Adams CB, Street DS, Crass M, Bossaer JB. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect? J Oncol Pharm Pract. 2016;22(6):784–9.
Article
CAS
PubMed
Google Scholar
Baxley AA, Doyin-Lipede OA, Razaq MA. Hypersensitivity to Cetuximab After Geographic Relocation. Am J Ther. 2018;25(6):e699–700.
Article
PubMed
Google Scholar
Owera R, Gill A, Haddadin S, et al. High incidence of hypersensitivity reactions to cetuximab infusions in mid-Missouri: Association with prior history of atopy. J Clin Oncol. 2008;26(15_suppl):20747.
Article
Google Scholar
Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol. 2011;127(5):1286–93.e6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Commins SP, Platts-Mills TAE. Allergenicity of Carbohydrates and Their Role in Anaphylactic Events. Curr Allergy Asthma Rep. 2010;10(1):29–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Michel S, Scherer K, Heijnen IAFM, Bircher AJ. Skin prick test and basophil reactivity to cetuximab in patients with IgE to alpha-gal and allergy to red meat. Allergy. 2014;69(3):403–5.
Article
CAS
PubMed
Google Scholar
Platts-Mills TAE, Schuyler AJ, Tripathi A, Commins SP. Anaphylaxis to the Carbohydrate Side Chain Alpha-gal. Immunol Allergy Clin North Am. 2015;35(2):247–60.
Article
PubMed
PubMed Central
Google Scholar
Lee JH, Kim JH, Kim TH, Kim S-C. Delayed mammalian meat-induced anaphylaxis confirmed by skin test to cetuximab. J Dermatol. 2013;40(7):577–8.
Article
PubMed
Google Scholar
Steinke JW, Platts-Mills TAE, Commins SP. The alpha-gal story: Lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Young I, Prematunge C, Pussegoda K, et al. Tick exposures and alpha-gal syndrome: A systematic review of the evidence. Ticks Tick Borne Dis. 2021;12(3):101674.
Article
PubMed
Google Scholar
Sharma SR, Karim S. Tick Saliva and the Alpha-Gal Syndrome: Finding a Needle in a Haystack. Front Cell Infect Microbiol. 2021;11:680264.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. The Lancet. 2012;379(9814):461–73.
Article
Google Scholar
Hamsten C, Starkhammar M, Tran TAT, et al. Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy. Allergy. 2013;68(4):549–52.
Article
CAS
PubMed
Google Scholar
Beaudouin E, Kanny G, Guerin B, et al. Unusual Manifestations of Hypersensitivity After a Tick Bite: Report of Two Cases. Ann Allergy Asthma Immunol. 1997;79(1):43–6.
Article
CAS
PubMed
Google Scholar
Fernández-Soto P, Dávila I, Laffond E, et al. Tick-bite-induced anaphylaxis in Spain. Ann Trop Med Parasitol. 2001;95(1):97–103.
Article
PubMed
Google Scholar
Hamsten C, Tran TAT, Starkhammar M, et al. Red meat allergy in Sweden: Association with tick sensitization and B-negative blood groups. J Allergy Clin Immunol. 2013;132(6):1431–4.e6.
Article
PubMed
PubMed Central
Google Scholar
Septfons A, Goronflot T, Jaulhac B, et al. Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016. Euro Surveill. 2019;24(11):1800134.
Article
PubMed
PubMed Central
Google Scholar
National Cancer Institute (U.S. Department of Health and Human Services). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017.
Vermorken JB, Trigo J, Hitt R, et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy. J Clin Oncol. 2007;25(16):2171–7.
Article
CAS
PubMed
Google Scholar
Van Cutsem E, Peeters M, Siena S, et al. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. J Clin Oncol. 2007;25(13):1658–64.
Article
PubMed
Google Scholar
Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J. Clin. Oncol. 2007; 25(18_suppl):4000.
Dupont B, Mariotte D, Clarisse B, et al. Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncol. 2014;10(14):2133–40.
Article
CAS
PubMed
Google Scholar
Burke E, Rockey M, Grauer D, et al. Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center. Med Oncol. 2017;34(4):51.
Article
PubMed
Google Scholar
Bavbek S, Kendirlinan R, Çerçi P, et al. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics. Int Arch Allergy Immunol. 2016;171(3–4):227–33.
Article
CAS
PubMed
Google Scholar
García-Menaya JM, Cordobés-Durán C, Gómez-Ulla J, et al. Successful Desensitization to Cetuximab in a Patient With a Positive Skin Test to Cetuximab and Specific IgE to Alpha-gal. J Investig Allergol Clin Immunol. 2016;26(2):132–4.
Article
PubMed
Google Scholar
Hong DI, Bankova L, Cahill KN, et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Rev Clin Immunol. 2012;8(1):43–54.
Article
CAS
PubMed
Google Scholar
Jerath MR, Kwan M, Kannarkat M, et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol. 2009;123(1):260–2.
Article
CAS
PubMed
Google Scholar
Pérez-Rodríguez E, Martínez-Tadeo JA, Pérez-Rodríguez N, et al. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol. J Allergy Clin Immunol Pract. 2018;6(5):1621–7.e6.
Article
PubMed
Google Scholar
Saif MW, Syrigos KI, Hotchkiss S, et al. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2009;65(1):107–12.
Article
CAS
PubMed
Google Scholar
Solduzian M, Anvari S, Taghvaye Masoumi H, et al. Successful desensitization of a patient with cetuximab hypersensitivity: A case report. J Oncol Pharm Pract. 2019;25(7):1726–30.
Article
PubMed
Google Scholar
Heun J, Holen K. Treatment with Panitumumab After a Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer: A Case Report. Clin Colorectal Cancer. 2007;6(7):529–31.
Article
PubMed
Google Scholar
Amgen, Incorporated. U.S. Food and Drug Administration. Vectibix (panitumumab) prescribing information. 2017.
Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). J Clin Oncol. 2006;24(18_suppl):3548.
Article
Google Scholar
Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18(1):7–15.
Article
CAS
PubMed
Google Scholar
Gibson TB, Ranganathan A, Grothey A. Randomized Phase III. Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2006;6(1):29–31.
Article
PubMed
Google Scholar
Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (< 1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol. 2006;24:3547. (18_suppl).
Article
Google Scholar